These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1498056)

  • 1. Breast cancer: adjuvant therapy with anthracyclines.
    Bonadonna G; Valagussa P
    Ann Oncol; 1992 Jun; 3(6):417-8. PubMed ID: 1498056
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant chemotherapy for breast cancer--30 years later.
    Levine MN; Whelan T
    N Engl J Med; 2006 Nov; 355(18):1920-2. PubMed ID: 17079767
    [No Abstract]   [Full Text] [Related]  

  • 3. Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer.
    Bonadonna G; Valagussa P; Veronesi U
    J Clin Oncol; 2008 Jan; 26(3):342-4. PubMed ID: 18202404
    [No Abstract]   [Full Text] [Related]  

  • 4. Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream.
    Di Leo A; Moretti E
    J Clin Oncol; 2008 Nov; 26(31):5011-3. PubMed ID: 18768431
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant therapy for early breast cancer.
    Costa SD; Bischoff J
    N Engl J Med; 2007 Mar; 356(12):1268-9. PubMed ID: 17377168
    [No Abstract]   [Full Text] [Related]  

  • 7. [Quality outcome of adjuvant CMF therapy in patients with breast cancer].
    Kleeberg UR
    Strahlenther Onkol; 2000 Jun; 176(6):290-1. PubMed ID: 10897257
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclophosphamide, methotrexate, and fluorouracil: still the gold standard?
    Hudis CA
    J Clin Oncol; 1996 Jul; 14(7):1971-3. PubMed ID: 8683226
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    Nielsen KV; Brünner N
    J Natl Cancer Inst; 2011 Feb; 103(4):352-3. PubMed ID: 21217082
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
    Aksoy S; Harputluoglu H; Guler N; Altundag K; Hayran M; Tekuzman G; Ozisik Y
    Breast J; 2007; 13(4):431-2. PubMed ID: 17593056
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant chemotherapy with cyclophosphamide methotrexate and 5-fluorouracil (CMF) in stage II breast cancer in Indian patients.
    Shetty PA; Sarda PK; Majumdar AT; Pai VR; Shinde SR; D'Souza LJ; Pinto JM; Jussawalla DJ
    Indian J Cancer; 1985 Sep; 22(3):239-44. PubMed ID: 3843327
    [No Abstract]   [Full Text] [Related]  

  • 12. Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer.
    Schmitt M; Sweep FC
    Eur J Cancer; 2009 Sep; 45(14):2444-6. PubMed ID: 19647994
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adriamycin/cyclophosphamide: current standard in the adjuvant therapy of breast carcinoma? Or: how should one really put this question?].
    Cavalli F
    Schweiz Med Wochenschr; 1994 Oct; 124(43):1882-4. PubMed ID: 7973514
    [No Abstract]   [Full Text] [Related]  

  • 14. What is the ideal duration of adjuvant therapy for primary breast cancer: are four cycles of cyclophosphamide and doxorubicin enough?
    Shulman LN
    Curr Oncol Rep; 2001 Nov; 3(6):523-8. PubMed ID: 11595121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy and subsequent malignant disease.
    Andersson M; Storm HH; Mouridsen HT
    Lancet; 1991 Oct; 338(8771):885-6. PubMed ID: 1681236
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant chemotherapy in breast cancer.
    Del Mastro L; Costantini M; Bianco AR
    N Engl J Med; 1995 Aug; 333(9):596; author reply 597. PubMed ID: 7623914
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal chemotherapy for women with breast cancer: the plot thickens.
    Pater JL; Pritchard KI
    J Clin Oncol; 2003 Mar; 21(6):963-4. PubMed ID: 12637457
    [No Abstract]   [Full Text] [Related]  

  • 18. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.
    Elledge RM; Gray R; Mansour E; Yu Y; Clark GM; Ravdin P; Osborne CK; Gilchrist K; Davidson NE; Robert N
    J Natl Cancer Inst; 1995 Aug; 87(16):1254-6. PubMed ID: 7563172
    [No Abstract]   [Full Text] [Related]  

  • 19. The expanding role of epirubicin in the treatment of breast cancer.
    Glück S
    Cancer Control; 2002; 9(2 Suppl):16-27. PubMed ID: 11965227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil.
    Diehl LF; Perry DJ; Tang DB
    J Clin Oncol; 1983 Oct; 1(10):663-4. PubMed ID: 6689422
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.